Macropa-NH2 (TFA)
Product Specifications
CAS Number
2705054-08-4
UNSPSC Description
Macropa-NH2 TFA is the precursor of Macropa-NCS. Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070 and is a promising therapeutic radionuclide applied in the treatment of soft-tissue metastases[1].
Target Antigen
Others
Type
Reference compound
Related Pathways
Others
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/macropa-nh2-tfa.html
Purity
98.03
Solubility
DMSO : ≥ 130 mg/mL|H2O : 100 mg/mL (ultrasonic)
Smiles
O=C(O)C1=NC(CN2CCOCCOCCN(CC3=NC(C(O)=O)=CC=C3)CCOCCOCC2)=CC(N)=C1.O=C(O)C(F)(F)F
Molecular Weight
661.62
References & Citations
[1]Thiele NA, et al. An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy. Angew Chem Int Ed Engl. 2017;56(46):14712-14717.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC471865-500 1x 500 µL
Napsin A (Lung Adenocarcinoma Marker) (NAPSA/1865R), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 